Peptilogics is an early-stage biotechnology company developing a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Through rational design, this technology dramatically amplifies the antimicrobial activity of naturally-occurring peptides while at the same time achieving a strong systemic safety profile. The eCAP platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/29/17 | $5,500,000 | Series A |
BlueTree Venture Fund Peter Thiel Stefan Roever | undisclosed |
| 12/22/20 | $35,400,000 | Series B |
Founders Fund Peter Thiel Presight Captial  | undisclosed |
